The inhibition of noscapine to CYP3A4 and CYP2C9: explanation for clinical DDI between noscapine and warfarin

被引：0
|
作者：
Fang, Zhong-Ze [1 ]
Yang, Ling [1 ]
机构：
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Lab Pharmaceut Resource Discovery, Dalian 116023, Peoples R China
来源：
DRUG METABOLISM REVIEWS | 2009年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
150
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [21] Principal Component Analysis of CYP2C9 and CYP3A4 Probe Substrate/Inhibitor Panels
    Nath, Abhinav
    Atkins, William
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (11) : 2151 - 2155
  • [22] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [23] NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes
    Surapureddi, Sailesh
    Rana, Ritu
    Goldstein, Joyce A.
    PHARMACOLOGICAL RESEARCH, 2011, 63 (05) : 405 - 413
  • [24] Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
    Adams, M
    Pieniaszek, HJ
    Gammaitoni, AR
    Ahdieh, H
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (03): : 337 - 345
  • [25] Genetic association between sensitivity to warfarin and expression of CYP2C9*3
    Steward, DJ
    Haining, RL
    Henne, KR
    Davis, G
    Rushmore, TH
    Trager, WF
    Rettie, AE
    PHARMACOGENETICS, 1997, 7 (05): : 361 - 367
  • [26] Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin
    Pavani, Addepalli
    Naushad, Shaik Mohammad
    Stanley, Balraj Alex
    Kamakshi, Renganathan Gnanambal
    Abinaya, Krishnan
    Rao, Malempati Amaresh
    Uma, Addepally
    Kutala, Vijay Kumar
    PHARMACOGENOMICS, 2015, 16 (04) : 393 - 400
  • [27] CONTRIBUTION OF UGT1A1, CYP2A6, CYP2C9, AND CYP3A4 IN METABOLISM OF BELINOSTAT
    Luo, Gang
    Schicker, Michael
    Lee, Deborah
    Leitz, Sara
    McKenzie, Donald
    Albaugh, Daniel
    Reddy, Guru
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S59 - S59
  • [28] Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans
    Guo, YJ
    Zhang, YF
    Wang, Y
    Chen, XY
    Si, DY
    Zhong, DF
    Fawcett, JP
    Zhou, H
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (06) : 749 - 753
  • [29] In Vitro Human Cytochrome P450 Isozymes (CYPs) Inhibition of Epifriedelanol on CYP2C9, CYP2E1 and CYP3A4
    Yu, Jie
    Zou, Fengxian
    Zhao, Lifang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1677 - 1683
  • [30] Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution
    Lauren B. Arendse
    Jonathan M. Blackburn
    Scientific Reports, 8
12345